Our Story
A leading regenerative medicine company committed to
driving change and improving patient outcomes
Our commitment to disruptive, meaningful innovation goes beyond mere advancement. It’s a dedication to setting new standards that challenge the status quo and push the limits of what’s possible. We believe innovation should be purposeful in how it improves the standards of care and ultimately, patient outcomes. If there is a better way, we will dream it up, and relentlessly strive to make it a reality.
“When Humacyte was first founded, many people thought our goal of creating an off-the-shelf human-derived vessel was the stuff of dreams. The twenty years of dedication that led to this point brought forth a new reality. We don’t take for granted the trust from our patients and caregivers in our platform. Every vessel and every person are an indelible part of our historic journey.”
revolutionizing the best science and technology to
improve and save the lives of those suffering from injury and disease.
Key facts:
Developed a
first-in-class
bioengineering
technology
and manufacturing
platform
Granted Regenerative Medicine Advanced Therapy (RMAT)
designation by the U.S. FDA
for the Acellular Tissue Engineered Vessel (ATEV™)
in Vascular Trauma,
AV Access, and PAD
Platform science has potential to be leveraged
across many clinical applications and indications
Highly scalable
cell sourcing and manufacturing are in place
Outreach
Humanitarian aid for vascular trauma injuries in Ukraine.
Our year-long humanitarian program in Ukraine, provided the investigational ATEV to five hospitals on the frontlines of the conflict, beginning in June 2022. At the request of Ukrainian surgeons, we worked closely with the International Office of the FDA and the Ukrainian Ministry of Health to obtain approval for the program. Training was conducted through video conference. In the end, nineteen patients were treated with ATEVs for vascular injuries during the program.
Results published in Journal of Vascular Surgery – Vascular Science
The ATEV used in this program is investigational and not approved by the U.S. Food and Drug Administration or any health authority. Its safety and effectiveness have not been established.
